Known as The Lighthouse Study, the Phase 1/2 trial is expected to begin in mid-2023

Atsena Receives FDA Authorization to Launch a Gene Therapy Clinical Trial for XLRS

MeiraGTx hopes to apply for marketing approval in the UK for the gene therapy.

LCA4 Gene Therapy Restores Meaningful Vision for Blind Children

The expanded Phase 1/2/3 shortens time to potential FDA approval.

Atsena Gets FDA Nod to Expand XLRS Gene Therapy Clinical Trial to Include Pivotal Phase 3 Cohort

The Foundation funded earlier, proof-of-concept studies for the Best1 gene therapy and later launched Opus to develop several IRD gene therapies.

Opus Genetics Receives FDA Clearance to Launch Clinical Trial for Best1 Gene Therapy

Lance Baldo, MD, CEO at Beacon Therapeutics, talks to host Ben Shaberman about his company's fully enrolled Phase 3 VISTA clinical trial for laru-zova, a gene therapy for X-linked retinitis pigmentosa (RPGR mutations) that's showed promising results in earlier trials. They also discuss Beacon's forthcoming clinical trial for its dry age-related macular degeneration gene therapy.

Eye on the Cure Podcast | Episode 92: Lance Baldo, MD

Durable vision improvements were also observed out to 18 months for previously dosed adult patients in the trial.

Opus Reports Vision Improvements for Three Pediatric Patients in Phase 1/2 Clinical Trial for LCA5 Gene Therapy

The Foundation Fighting Blindness is the driving force in the global development of treatments and cures for blinding diseases. To learn more, go to FightingBlindness.org.

New tracks tagged #genetherapies